Sanara MedTech : Management Change/Compensation Form 8 K
June 19, 2024 at 03:18 pm IST
Share
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on June 12, 2024, at the 2024 Annual Meeting of Shareholders (the "Annual Meeting") of Sanara MedTech Inc. (the "Company"), the Company's shareholders approved the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan (the "2024 LTIP"). As a result, the 2024 LTIP became effective on June 12, 2024. A description of the material terms of the 2024 LTIP is included under the heading "Proposal 4: Approval of the Adoption of the 2024 Plan" in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2024, as supplemented on May 15, 2024. Such description is qualified in its entirety by reference to the full text of the 2024 LTIP, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Attachments
Original Link
Permalink
Disclaimer
Sanara Medtech Inc. published this content on
18 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
19 June 2024 09:47:04 UTC.
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
SANARA MEDTECH INC. 
